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Materials and Methods
Chemicals. Digoxin and verapamil were purchased from Sigma-Aldrich, Co. (MO, USA).
Elacridar and cyclosporin A were from Toronto Research Chemicals, Inc (North York, Canada).
Itraconazole was from MP Biomedicals, LLC (Tokyo, Japan). Ketococonazole and quinidine were from Wako Pure Chemicals Industries (Osaka, Japan). All other chemicals were the highest reagent grade available from commercial sources.
Cell culture. The rat Mdr1a and human MDR1-expressing LLC-PK1 cells were cultured using a method obtained by slight modification of that reported in the literature (Takeuchi et al., 2006) .
Briefly, cells were incubated in complete culture medium consisting M199 (Invitrogen, Carlsbad, CA) or DMEM (Dulbecco's modified Eagle's medium: Invitrogen) with 20% fetal bovine serum (Invitrogen), 500 μ g/mL G418 and 150 ng/mL colchicine. Cells were split bi-weekly at a ratio of 1:5-10 and grown in an atmosphere of 5%CO 2 -95%O 2 at 37ºC. Rat Mdr1a-and human MDR1-expressing LLC-PK1 cells were harvested with trypsin and seeded on microporous polycarbonate membrane filters at a cell density of 2.25×10 5 cells/mL in 24-well insert plates (TranswellTM, 3397, Corning, Acton, MA) and 2.25×10 6 cells/mL in 96-well insert plates (TranswellTM, 3391, Corning) , respectively. These plates were incubated in an atmosphere of 5%CO 2 -95%O 2 at 37ºC. Fresh medium was added on the third or fourth day and transcellular transport study was taken place on the seventh day after seeding.
Transcellular transport study. Before the start of the transcellular transport study, all culture media were replaced with the fresh M199 medium including 10 mmol/L HEPES at pH 7.4.
Inhibitory effects on vectorial transport of digoxin were investigated by adding P-gp inhibitors to the medium on both sides of the transwell chamber for 30 min before adding substrates. The 5%CO 2 -95%O 2 at 37ºC for 1 or 2 h, respectively. Lucifer yellow (LY) (200 μ mol/L) was used in every transwell along with digoxin and inhibitors to monitor the monolayer integrity. Aliquots from the receiver side were taken at time where the linearity of the transcellular transport of digoxin was observed. The LY concentration in the receiver chamber was determined with fluorescence intensity.
Excitation and emission wavelengths were set as 485 and 528 nm. The permeability coefficient of LY should be less than 15 nm/sec for the acceptable assay condition.
Data analysis for the transcellular transport study. The modified corrected flux ratio (MCFR) was defined as the flux ratio in MDR1-expressing LLC-PK1 cells divided by the corresponding ratio in functionally MDR1-inhibited cells using a potent P-gp inhibitor, elacridar. According to the compartment model shown in Fig.1 , MCFR across MDR1-expressing cells/MDR1-inhibited cells can be determined using equation 4.
( Intravenous infusion of digoxin in the presence or absence of P-gp inhibitors in rats. Rats were placed under anesthesia with diethyl ether, the femoral vein was cannulated with a 3.0-Fr (ID:
0.58 mm, OD: 0.94 mm) catheter. Rats were attached to the free-moving system (Eicom Inc., Kyoto, Japan, Tsumura Inc., Tokyo, Japan) during experiments. The catheter was inserted through an incision in the cervical division to attach the free-moving system. Digoxin (0.06 mg/h/kg) was administered by a constant rate intravenous infusion via the femoral vein to achieve steady-state plasma concentration in the presence or absence of P-gp inhibitors. N-methyl-2-pyrrolidone (NMP)/saline (1:1) and dimethylacetamide (DMA)/saline (1:1) mixtures were used as dosing vehicle for elacridar and other P-gp inhibitors, respectively. Elacridar (0.125, 0.25, 0. 5, 1, 2
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Determination of plasma protein binding.
The unbound fraction in rat and human plasma was determined using the 96-well equilibrium dialysis apparatus (HTDialysis, LLC, Connecticut, USA). The control rat plasma was pooled and kept at -80ºC until the plasma protein binding experiment. The control pooled human plasma was purchased from KAC (Kyoto, Japan). The tested compounds was added into the control plasma (the of 0.05% (w/v) ammonium carbonate, pH 9 and methanol, respectively. The initial concentration of mobile phase B was 10%, and this condition was maintained for 0.2 min, followed by a linear increase of B to 95% over 2.8 min, held for 0.8 min. The condition was then returned to the initial concentration and held for 1.2 min for re-equilibration. The lower limit of quantification of digoxin in rat plasma and brain were 1 ng/mL and 5 ng/g brain, respectively. The standard curve was linear (r 2 > 0.999) over the digoxin concentrations of 1-300 ng/mL (rat plasma) and 5-1500 ng/g (rat brain).
Plasma concentrations of P-gp inhibitors were determined using a MS/MS apparatus (API4000) equipped with a UFLC. Briefly, 50 μ L of plasma sample and 20% brain homogenate sample were mixed 200 μ L of acetonitrile and 10 μ L of alprenolol (1 μ g/mL) as an internal standard, followed by centrifugation at 4 ºC, 5250 rpm for 5 min. The supernatant was diluted with 3 volumes of 10 mmol/L ammonium formate, and drug concentrations were determined. The analytical column used was Shim-pack XR-ODS, C18 column (20 mm × 2.0 mm, 5 μ m) from Shimadzu Co. Ltd.
(Kyoto, Japan). The total run time, flow rate and column temperature were 2.6 min, 0.5 mL/min, and 50 ºC, respectively. Mobile phase A and B consisted of 10 mmol/L ammonium formate, pH 3 and acetonitrile, respectively. The initial concentration of mobile phase B was 10% and this condition was maintained for 0.2 min, followed by a linear increase of B to 95% over 0.2 min, held for 1 min. The initial concentration was then reinstated and held for 1.2 min for re-equilibration.
Accuracy of standards and inter-assay variability were within ± 15%. Detailed MS conditions were shown in Table 1 .
Sigmoidal dose-response to calculate EC 50 . The apparent EC 50 (Fig. 3C ) of the elacridar at half maximal increase of K p,brain of digoxin was calculated in GraphPad Prism version 5.00 for Windows, GraphPad Software (San Diego , USA) using the following equation:
Bottom: 
Results
Inhibition of rat Mdr1a-mediated digoxin transport by P-gp inhibitors. To investigate the inhibitory potency of P-gp inhibitors (elacridar, itraconazole, cyclosporin A, ketoconazole, verapamil, and quinidine), we performed a transcellular transport study in rat Mdr1a-expressing LLC-PK1 cells using digoxin as a probe substrate of P-gp. In vitro K i values for digoxin transport via rat Mdr1a were calculated according to the intersections of Dixon plots (Fig. 2) . Elacridar showed the most potent P-gp inhibitory effect among six P-gp inhibitors tested (Table 2) .
Drug interaction study of digoxin and elacridar in rats. To elucidate the effect of P-gp inhibition on the digoxin transport to the brain, intravenous infusion of digoxin in the presence or absence of elacridar was performed in rats. During the infusion of digoxin and elacridar, the plasma concentration reached steady-state ( Fig. 3A and B) . The brain-to-plasma concentration ratio (K p,brain )
of digoxin was measured at 8 h after the initiation of administration. Elacridar notably increased 
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Discussion P-gp is a well-studied ABC transporter, and potential P-gp-mediated DDI studies are currently focused on drug candidates especially acting on the central nerve system (Tsuji, 2006; Feng et al., 2008) . However, little quantitative information is available regarding potential P-gp-mediated DDIs at the BBB. We have therefore quantitatively investigated the impact of P-gp inhibition through the use of in vitro-in vivo correlation at the rat BBB.
In vitro P-gp inhibition studies have been performed in pharmaceutical industries and academic fields to predict in vivo DDI of digoxin. However, the evaluation method of in vitro P-gp inhibitory activity has been still controversial (Adachi et al., 2001; Keogh and Kunta, 2006; Rautio et al., 2006) . A major challenge of in vitro P-gp inhibition study is to theoretically and accurately determine the intrinsic efflux activity (PS P-gp in Fig. 1 ). An additional challenge is to correct the influence of the different passive permeability between rat Mdr1a and mock cells. The third challenge is to ascertain in vitro K i values that are independent of the affinity and concentration of probe substrates. To overcome these issues, we employed a theoretical approach to ascertain in vitro mediate the efflux process, but also the influx process. P-gp and BCRP (breast cancer resistance protein) are representative transporters of the efflux process and OATP (organic anion transport peptides) is a representative transporter of the influx process. In terms of the efflux transporter, P-gp plays a significant role in transporting digoxin in vitro and in vivo, but not BCRP (Pavek et al., 2005) . For the influx transporter, one subtype of the OATP family (Oatp1a4) may play a role in the transport of digoxin as well as P-gp in rats. Oatp1a4 is expressing in both the luminal and anti-luminal membrane of the BBB and plays a role in the uptake of organic anionic compounds (i.e.
estradiol-17β-glucuronide, statins, and taurocholate) (Noe et al., 1997; Gao et al., 1999) . However, a recent study using Oatp1a4 (-/-) mice revealed that the blood-to-brain uptake of digoxin was not significantly different between Oatp1a4 (-/-) and wild-type mice unless Oatp1a4 (-/-) mice were pretreated with elacridar (Ose et al., 2010) . Although a species difference of the function of Oatp1a4 between rats and mice is arguable, OATP may have a much less impact than P-gp on the digoxin transport to the rat brain. Hence, the evaluation of K p,brain of digoxin in the presence or absence of P-gp inhibitors is a rational approach to understand the impact of P-gp-mediated DDI at the rat BBB.
The magnitude of P-gp inhibition at the BBB was evaluated in rats. In the presence of elacridar in the rat plasma, K p,brain of digoxin was increased by approximately 14-fold over the control (Fig. 3C ).
This result was comparable to a previous report in which K p,brain of digoxin in Mdr1a/1b (-/-) mice was about 19-fold higher than that in wild-type mice (Schinkel et al., 1994) . Additionally, the apparent EC 50 of elacridar plasma concentration to achieve chemically induced P-gp knockout in rats was 266 ng/mL. This result was also comparable to the previous report (EC 50 ≈ 320 ng/mL) using SB-487946 as P-gp probe substrate (Cutler et al., 2006) . The unbound EC 50 was approximately 2.7 ng/mL (4.7 nmol/L), which was in good agreement with the in vitro K i value (Table 2 ). These results indicated that elacridar was the useful compound to investigate the maximum effect by P-gp inhibition at the rat BBB. In order to estimate the effect of clinically used P-gp inhibitors on the digoxin transport, itraconazole, cyclosporin A, ketoconazole, verapamil, and quinidine were selected, because these drugs have been concomitantly administered with digoxin in clinical trials
This article has not been copyedited and formatted. The final version may differ from this version. (Angelin et al., 1987; Dorian et al., 1988; Hedman et al., 1991; Jalava et al., 1997b; Larsen et al., 2007) . The K p,brain of digoxin significantly increased in the presence of cyclosporin A, but not other P-gp inhibitors. This experimental result can be explained by the fact that cyclosporin A showed a relatively strong P-gp inhibitory effect (K i : 0.038 μ mol/L, Table 2 ) among P-gp inhibitors and has sufficient exposure in rat plasma (~3000 ng/mL). Consequently, P-gp-mediated DDI of digoxin at the rat BBB may be observed under sufficient exposure of potent P-gp inhibitors in rat plasma.
In order to quantify P-gp-mediated DDIs at the rat BBB, we employed the IVIV approach.
According Based on the assumption that there is little species difference in both intrinsic activity and expression level of P-gp between rats and human, we examined the possibility of P-gp-mediated DDI at the human BBB taking in vitro K i values in human MDR1 and plasma concentration at the conventional therapeutic dose into account. In vitro K i values were determined using MCFR in human MDR1-expressing LLC-PK1 cells and were summarized in loperamide was reported with a concomitant administration of quinidine at a dose of 600 mg (Sadeque et al., 2000) , relatively higher than the conventional clinical dosage (Brunton et al., 2005) .
This result can be explained by the fact that quinidine likely causes P-gp inhibition at a high dosage.
It is also notable that the plasma protein binding of quinidine is relatively lower than other P-gp inhibitors. Based on the IVIVC relationship, we assume that P-gp-mediated DDI at the human BBB may be limited because no compound showed [I ,unbound /K i ] > 1 at clinical doses (Table 4) .
To date, neither the species difference of expression level of mdr1a / MDR1 nor the anatomical structure in the cerebral endothelial cells, which may affect the accurate understandings of P-gp related DDI at the BBB, has been clarified. Further studies are required to address these issues.
In summary, this is the first quantitative IVIVC investigation to evaluate the impact of P-gp inhibition on the digoxin transport across the rat BBB. The degree of in vitro P-gp inhibition was evaluated by K i values using MCFR, which reflected the intrinsic P-gp efflux activity. The effect of 
